Original article Impact of L-DOPA treatment of patients with Parkinson’s disease on mononuclear subsets and phagocytosis in the peripheral blood

Hurny, Artur; Michałowska-Wender, G; Wender, M

doi:10.5114/fn.2013.35955

Cited by 9 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, a decrease in dopaminergic neurotransmission in prodromal PD will affect both innate and adaptive immune responses. Equally, dopaminergic drugs might affect immune cells as shown in several studies analysing T-cells in PD patients [ 109, 110 ].…”

Section: Neurotransmitters With Immunomodulatory Capacitymentioning

confidence: 99%

Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies

Terkelsen

Klæstrup

Hvingelby

et al. 2022

JPD

View full text Add to dashboard Cite

Multiple lines of clinical and pre-clinical research support a pathogenic role for neuroinflammation and peripheral immune system dysfunction in Parkinson’s disease. In this paper, we have reviewed and summarised the published literature reporting evidence of neuroinflammation and peripheral immune changes in cohorts of patients with isolated REM sleep behaviour disorder and non-manifesting carriers of GBA or LRRK2 gene mutations, who have increased risk for Parkinsonism and synucleinopathies, and could be in the prodromal stage of these conditions. Taken together, the findings of these studies suggest that the early stages of pathology in Parkinsonism involve activation of both the central and peripheral immune systems with significant crosstalk. We consider these findings with respect to those found in patients with clinical Parkinson’s disease and discuss their possible pathological roles. Moreover, those factors possibly associated with the immune response, such as the immunomodulatory role of the affected neurotransmitters and the changes in the gut-brain axis, are also considered.

show abstract

Section: Neurotransmitters With Immunomodulatory Capacitymentioning

confidence: 99%

Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies

Terkelsen

Klæstrup

Hvingelby

et al. 2022

JPD

View full text Add to dashboard Cite

show abstract

“…Moreover, the ratio of CD95/CD3 increases in the lymphocytes of PD patients; however, after L-dopa treatment, it decreases significantly [11]. Thus, it is evident that the cluster of differentiation families plays a significant role in the pathology of PD.…”

Section: Introductionmentioning

confidence: 96%

Immune-associated biomarkers for early diagnosis of Parkinson’s disease based on hematological lncRNA–mRNA co-expression

Lei

Zhang²,

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Early stage diagnosis of Parkinson's disease (PD) is challenging without significant motor symptoms. The identification of effective molecular biomarkers as a hematological indication of PD may help improve the diagnostic timeliness and accuracy. In this paper, we analyzed and compared the blood samples of PD and control (CTR) patients to identify the disease-related changes and determine the putative biomarkers for PD diagnosis. Based on the RNA sequencing analysis, differentially expressed genes (DEGs) were identified, and the co-expression network of DEGs was constructed using the weighted correlation network analysis (WGCNA). The analysis leads to the identification of 87 genes that were exclusively regulated in the PD group, whereas 66 genes were significantly increased and 21 genes were significantly decreased in contrast to the control group. The results indicate that the core lncRNA-mRNA co-expression network greatly changes the immune response in PD patients. Specifically, the results showed that PWAR6, LINC00861, AC83843.1, IRF family, IFIT family and CaMK4 may play important roles in the immune system of PD. Based on the findings from this the present study, future research aims at identify novel therapeutic strategies for PD.

show abstract

“…: +2882333938, fax: +2882366503, email: khaledradad@hotmail.com kiewicz in 1961 [3]. Interestingly, Hurny et al [13] have shown recently that levodopa decreased the CD 25 /CD 3 ratio, the antigen marker characteristic of apoptotic death within the T/CD 3 (+) lymphocyte population in the peripheral blood of PD patients. However, longterm levodopa treatment therapy is accompanied by abnormal involuntary movements known as levodopainduced dyskinesia [1].…”

Section: Introductionmentioning

confidence: 99%

Original article Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture

Radad

Scheller²,

Rausch³

et al. 2014

View full text Add to dashboard Cite

show abstract

Original article Impact of L-DOPA treatment of patients with Parkinson’s disease on mononuclear subsets and phagocytosis in the peripheral blood

Abstract: A Ar rt tu ur r H Hu ur rn ny y 1 1 , , G Gr ra aż ży yn na a M Mi ic ch ha ał ło ow ws sk ka a--W We en nd de er r

Cited by 9 publications

References 11 publications

Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies

Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies

Immune-associated biomarkers for early diagnosis of Parkinson’s disease based on hematological lncRNA–mRNA co-expression

Original article Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture

Contact Info

Product

Resources

About